Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lisziewicz

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Current Medicinal Chemistry|August 21, 2007
Nanochemistry-based immunotherapy for HIV-1F Lori, S A Calarota, J Lisziewicz
The New Biologist|January 1, 1991
Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expressionJ Lisziewicz, J Rappaport, R Dhar
Current Pharmaceutical Design|December 8, 2004
"Virostatics" as a potential new class of HIV drugsL M Kelly, J Lisziewicz, F Lori
The Journal of Infectious Diseases|October 23, 1997
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapyA De Antoni, A Foli, J Lisziewicz, et al.
The Journal of Biological Chemistry|February 25, 1987
Isolation and nucleotide sequence of a Saccharomyces cerevisiae protein kinase gene suppressing the cell cycle start mutation cdc25J Lisziewicz, A Godany, H H Förster, et al.
Gene Therapy|May 1, 1995
Antitat gene therapy: a candidate for late-stage AIDS patientsJ Lisziewicz, D Sun, A Lisziewicz, et al.
Nucleic Acids Research|December 23, 1988
Cloning and characterization of the Saccharomyces cerevisiae CDC6 geneJ Lisziewicz, A Godany, D V Agoston, et al.
Current Medicinal Chemistry|February 3, 2007
Virostatics: a new class of anti-HIV drugsF Lori, A Foli, L M Kelly, et al.
Journal of Molecular Biology|February 27, 1999
Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptaseP L Boyer, J Lisziewicz, F Lori, et al.
Journal of Biological Regulators and Homeostatic Agents|May 11, 2002
Role of hydroxyurea during structured treatment interruptionsA Foli, E Seminari, E Ravot, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Current Medicinal Chemistry|August 21, 2007
Nanochemistry-based immunotherapy for HIV-1F Lori, S A Calarota, J Lisziewicz
The New Biologist|January 1, 1991
Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expressionJ Lisziewicz, J Rappaport, R Dhar
Current Pharmaceutical Design|December 8, 2004
"Virostatics" as a potential new class of HIV drugsL M Kelly, J Lisziewicz, F Lori
The Journal of Infectious Diseases|October 23, 1997
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapyA De Antoni, A Foli, J Lisziewicz, et al.
The Journal of Biological Chemistry|February 25, 1987
Isolation and nucleotide sequence of a Saccharomyces cerevisiae protein kinase gene suppressing the cell cycle start mutation cdc25J Lisziewicz, A Godany, H H Förster, et al.
Gene Therapy|May 1, 1995
Antitat gene therapy: a candidate for late-stage AIDS patientsJ Lisziewicz, D Sun, A Lisziewicz, et al.
Nucleic Acids Research|December 23, 1988
Cloning and characterization of the Saccharomyces cerevisiae CDC6 geneJ Lisziewicz, A Godany, D V Agoston, et al.
Current Medicinal Chemistry|February 3, 2007
Virostatics: a new class of anti-HIV drugsF Lori, A Foli, L M Kelly, et al.
Journal of Molecular Biology|February 27, 1999
Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptaseP L Boyer, J Lisziewicz, F Lori, et al.
Journal of Biological Regulators and Homeostatic Agents|May 11, 2002
Role of hydroxyurea during structured treatment interruptionsA Foli, E Seminari, E Ravot, et al.
Pageof 6